Virology & Infectious Diseases RFP Opportunities
Gilead Sciences funds innovative research in HIV, invasive fungal infections, and hepatitis to advance clinical practice and patient outcomes in virology and infectious diseases.
Funder: Gilead Sciences
Due Dates: January 30, 2026 (LOI – HIV Prevention: INCLUSION Global 2026) | April 3, 2026 (Full – HIV Prevention: INCLUSION Global 2026) | May 4, 2026 (LOI – HIV: RESONATE 2026) | May 29, 2026 (Full – HIV: RESONATE 2026) | June 30, 2026 (LOI – AmBisome)
Funding Amounts: Up to $5,000,000 (INCLUSION Global 2026) | Up to $4,000,000 (RESONATE 2026) | Typical project duration: 18–24 months | Overhead max: 30%
Summary: Supports high-impact research projects in HIV prevention and management, invasive fungal infections, and hepatitis B, C, and D to advance clinical practice and patient outcomes in virology and infectious diseases.
Key Information: LOIs required for most programs; only specific countries eligible for some RFPs; applications via Gilead OPTICS portal.
Description
Gilead Sciences' Virology & Infectious Diseases RFP Opportunities provide substantial research funding for projects that address urgent needs in HIV prevention and management, invasive fungal infections (notably AmBisome), and hepatitis B, C, and D. The program aims to support innovative research that advances clinical practice, improves patient outcomes, and addresses evolving challenges in virology and infectious diseases. Funding is available for investigator-initiated and collaborative studies, with a focus on implementation, outcomes, and real-world effectiveness.
